A Practical Guide to Prescribing CBD for Drug-Resistant Epilepsy
This clinical guide synthesizes the practical aspects of prescribing pharmaceutical CBD (Epidiolex) for drug-resistant epilepsy—covering dosing, drug interactions, side effects, and the critical importance of starting low and going slow.
Quick Facts
What This Study Found
While CBD's efficacy for certain severe epilepsy syndromes is established (Dravet, Lennox-Gastaut), the practical details of prescribing it safely remain challenging. This review fills that gap with evidence-based clinical guidance.
The "start low, go slow" principle is central. CBD interacts with many common anti-seizure medications through the cytochrome P450 enzyme system, particularly affecting clobazam (whose active metabolite levels can double or triple with CBD co-administration) and valproate (increasing the risk of liver enzyme elevation). Gradual dose titration allows clinicians to monitor for these interactions.
Adverse drug reactions are dose-dependent and generally manageable: sedation (especially when combined with clobazam), gastrointestinal effects, decreased appetite, and elevated liver enzymes (particularly with valproate). The liver enzyme issue requires regular monitoring but is typically reversible with dose adjustment.
The review also addresses a practical reality: roughly 30% of epilepsy patients are drug-resistant (failing two or more conventional medications), and these patients often have complex medication regimens. Adding CBD to this polypharmacy requires careful attention to interactions that could either reduce the effectiveness of existing medications or amplify their side effects.
Key Numbers
~30% of epilepsy patients are drug-resistant. Highly purified CBD (Epidiolex) is 99% CBD. Clobazam active metabolite levels can increase 2–3x with CBD co-administration. Liver enzyme elevation risk highest with valproate combination. "Start low, go slow" dosing approach recommended.
How They Did This
Narrative review synthesizing clinical trials, systematic reviews, observational studies, and real-world evidence on practical aspects of prescribing highly purified CBD oral solution (Epidiolex) for drug-resistant epilepsy.
Why This Research Matters
Having an effective drug is only useful if clinicians know how to prescribe it safely. CBD's drug interactions are clinically significant—a patient taking clobazam who starts CBD may suddenly become over-sedated if the interaction isn't anticipated and managed. This practical guide helps bridge the gap between FDA approval and real-world clinical use.
The Bigger Picture
This clinical implementation review complements the broader epilepsy-cannabis evidence reviewed in RTHC-00165, the novel CBD formulations being tested in RTHC-00179 (DehydraTECH) and RTHC-00160 (carvone-derived analogues), and the general CBD pharmacology covered in RTHC-00184. As CBD-based epilepsy treatment moves from research into routine clinical practice, guides like this become essential for safe prescribing.
What This Study Doesn't Tell Us
Narrative review reflects the author's clinical perspective and evidence selection. Most evidence comes from the specific FDA-approved formulation (Epidiolex 99% CBD)—results may not apply to other CBD products. Drug interaction data is still evolving. The review focuses on severe epilepsy syndromes and may not generalize to milder forms or off-label use.
Questions This Raises
- ?Would personalized dosing based on genetic CYP450 profiles improve outcomes?
- ?How should clinicians manage the transition from unregulated CBD products to pharmaceutical-grade Epidiolex?
- ?Are there epilepsy types beyond Dravet and Lennox-Gastaut where CBD should be tried?
Trust & Context
- Key Stat:
- Evidence Grade:
- Narrative review synthesizing clinical evidence with practical prescribing guidance—rated moderate due to the strong underlying RCT evidence for Epidiolex.
- Study Age:
- Published in 2025 with current prescribing data and interaction evidence.
- Original Title:
- Practical approach to the safe use of cannabidiol in patients with refractory epilepsy: a mini review.
- Published In:
- Frontiers in pharmacology, 16, 1681815 (2025) — Frontiers in Pharmacology is a reputable journal focusing on pharmacological research and drug development.
- Authors:
- Navarro, Cristian E(2)
- Database ID:
- RTHC-07241
Evidence Hierarchy
Summarizes existing research without a strict systematic method.
What do these levels mean? →Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-07241APA
Navarro, Cristian E. (2025). Practical approach to the safe use of cannabidiol in patients with refractory epilepsy: a mini review.. Frontiers in pharmacology, 16, 1681815. https://doi.org/10.3389/fphar.2025.1681815
MLA
Navarro, Cristian E. "Practical approach to the safe use of cannabidiol in patients with refractory epilepsy: a mini review.." Frontiers in pharmacology, 2025. https://doi.org/10.3389/fphar.2025.1681815
RethinkTHC
RethinkTHC Research Database. "Practical approach to the safe use of cannabidiol in patient..." RTHC-07241. Retrieved from https://rethinkthc.com/research/navarro-2025-practical-approach-to-the
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.